These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22257604)

  • 1. [Spanish cultural adaptation and psychometrical validation of the Treatment Benefit Scale (TBS) in the symptomatic treatment of overactive bladder].
    Errando-Smet C; Ruiz MA; Villacampa-Aubá F; Arlandis-Guzmán S; Rejas J; Ruiz L; García-Vargas M
    Med Clin (Barc); 2013 Jan; 140(1):6-13. PubMed ID: 22257604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.
    Arlandis S; Ruiz MA; Errando C; Villacampa F; Arumí D; Lizarraga I; Rejas J
    Clin Drug Investig; 2012 Aug; 32(8):523-32. PubMed ID: 22741748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool.
    Villacampa F; Ruiz MA; Errando C; Arlandis S; Arumí D; Lizarraga I; Rejas J
    Int Urogynecol J; 2013 Apr; 24(4):573-81. PubMed ID: 23111865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Psychometric validation of the OAB-V8 and OAB-V3 scales for the screening of patients with probable overactive bladder in the Spanish population].
    Brenes FJ; Angulo JC; Ochayta D; Rejas J; Arumí D; Cañadas A; Lizarraga I
    Med Clin (Barc); 2014 Dec; 143(12):521-9. PubMed ID: 24725856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
    Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
    Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliability and validity of the Overactive Bladder Symptom Score in Spanish (OABSS-S).
    Weinberg AC; Brandeis GH; Bruyere J; Tsui JF; Weiss JP; Rutman MP; Blaivas JG
    Neurourol Urodyn; 2012 Jun; 31(5):664-8. PubMed ID: 22488591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to fesoterodine in women with overactive bladder in routine clinical practice.
    Simó M; Porta O; Pubill J; Castillo MT; Mora I; Huguet E; Ortega JA; Martínez E
    Actas Urol Esp; 2015 May; 39(4):222-8. PubMed ID: 25442908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder.
    Colman S; Chapple C; Nitti V; Haag-Molkenteller C; Hastedt C; Massow U
    Urology; 2008 Oct; 72(4):803-7. PubMed ID: 18722655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptom score change and patient versus doctor satisfaction in overactive bladder before and after anti-muscarinic treatment.
    Bunyavejchevin S
    J Obstet Gynaecol Res; 2015 Jun; 41(6):957-61. PubMed ID: 25773663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should we use the shorter Thai-version quality of life and symptoms questionnaires in women with overactive bladder?
    Bunyavejchevin S; Liao L; Lu SH; Choo MS; Rabbani KJ; Havanond P
    J Obstet Gynaecol Res; 2015 Aug; 41(8):1260-5. PubMed ID: 26081949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychometric properties of the incontinence utility index among patients with idiopathic overactive bladder: data from two multicenter, double-blind, randomized, Phase 3, placebo-controlled clinical trials.
    Castejón N; Khalaf K; Ni Q; Cuervo J; Patrick DL
    Health Qual Life Outcomes; 2015 Aug; 13():116. PubMed ID: 26231052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
    Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
    Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of symptom improvement on patients' bother and quality of life in female patients with overactive bladder treated by solifenacin (SET-Q).
    Gotoh M; Kobayashi T; Sogabe K
    Int J Urol; 2014 May; 21(5):505-11. PubMed ID: 24304092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for the failure of antimuscarinic treatment with solifenacin in women with overactive bladder.
    Serati M; Braga A; Siesto G; Sorice P; Cattoni E; Uccella S; Cromi A; Salvatore S; Ghezzi F
    Urology; 2013 Nov; 82(5):1044-8. PubMed ID: 24054438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden.
    Peeker R; Samsioe G; Kowalski J; Andersson AS; Bergqvist A
    Scand J Urol Nephrol; 2010 Apr; 44(3):138-46. PubMed ID: 20367449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
    Sánchez-Ballester F; Miranda P; Lizarraga I; Rejas J; Arumi D
    Actas Urol Esp; 2014 Apr; 38(3):156-63. PubMed ID: 24119382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies.
    Kelleher CJ; Dmochowski RR; Berriman S; Kopp ZS; Carlsson M
    BJU Int; 2012 Aug; 110(3):392-400. PubMed ID: 22129365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.